Clinical Trials Sponsored by Centene Corporation

Total 70059 results

Fox Chase Cancer Center
Celgene Corporation; Seagen Inc.

Active, not recruiting

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL)

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; Celgene Corporation

Completed

PKC412 and 5-Azacytidine

Leukemia

United States
Masonic Cancer Center, University of Minnesota
Celgene Corporation

Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Michigan Rogel Cancer Center
Celgene Corporation

Completed

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Bladder Cancer

United States
Jonsson Comprehensive Cancer Center
Celgene Corporation; CTI BioPharma

Terminated

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Celgene Corporation
ICON Clinical Research

Completed

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Myelodysplastic Syndromes

Germany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
Celgene Corporation
Prologue Research International

Terminated

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Celgene Corporation
Prologue Research International

Completed

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkins Lymphoma

United States
Celgene Corporation
Prologue Research International

Completed

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States, Canada
Celgene Corporation
Prologue Research International

Completed

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
Celgene Corporation
Prologue Research International

Terminated

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Celgene Corporation
Prologue Research International

Terminated

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Pancreatic Cancer

United States
Celgene Corporation
Prologue Research International

Completed

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Celgene Corporation
Prologue Research International

Terminated

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Prostate Cancer

United States
Hackensack Meridian Health
Celgene Corporation

Completed

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL (RICER)

Diffuse Large B Cell Lymphoma

United States
George Washington University
Celgene Corporation

Withdrawn

Apremilast and Moderate to Severe Chronic Hand Dermatitis (CHD)

Chronic Hand Dermatitis

United States
Hackensack Meridian Health
Celgene Corporation

Completed

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (FCR)

Chronic Lymphocytic Leukemia (CLL)

United States
PETHEMA Foundation
Celgene Corporation; Amgen

Active, not recruiting

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Spain
NYU Langone Health
Celgene Corporation

Completed

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Discoid Lupus Erythematosus

United States
West Virginia University
Celgene Corporation

Withdrawn

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Non-small Cell Lung Cancer

United States
University of Utah
Celgene Corporation

Completed

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (VA)

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Breast Cancer

United States
University Hospital, Lille
Celgene Corporation

Completed

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (RV-WM-0426)

Waldenstrom Macroglobulinemia

France
Virginia Commonwealth University
Celgene Corporation

Completed

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Agios Pharmaceuticals, Inc.
Celgene Corporation

Completed

Food Effect Study of AG-221 in Healthy Male Subjects

Healthy Volunteers

United States
University of Arkansas
Celgene Corporation

Completed

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Multiple Myeloma

United States
University Hospital, Lille
Celgene Corporation

Completed

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (IFM2009-02)

Multiple Myeloma

France
Georgetown University
Celgene Corporation; Cephalon

Completed

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (Phase I BLR)

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States
University Hospital, Grenoble
Celgene Corporation

Unknown

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs (MYELAXAT)

Venous Thromboembolism | Myeloma

France
University of Oklahoma
Celgene Corporation

Terminated

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Technische Universität Dresden
Celgene Corporation

Terminated

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes (AZALE)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Germany
Technische Universität Dresden
Celgene Corporation

Terminated

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (LENAMAINT)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Germany
The Cleveland Clinic
Celgene Corporation

Withdrawn

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

Portal Hypertension | Gastrointestinal Hemorrhage

United States
Veeda Oncology
Bayer; Celgene Corporation

Terminated

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
University of Arkansas
Celgene Corporation

Completed

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

United States
Johns Hopkins University
Celgene Corporation

Completed

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

Idiopathic Pulmonary Fibrosis (IPF)

United States
University of Leipzig
Celgene Corporation

Recruiting

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions (LENNON)

Myelodysplastic Syndromes | Anemia

Germany
University of Pennsylvania
Celgene Corporation

Completed

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States
Hackensack Meridian Health
Celgene Corporation

Terminated

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (VZCLLPI0146)

Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)

United States
AbbVie
Genentech, Inc.; Celgene Corporation

Withdrawn

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Multiple Myeloma

United States, Australia, Canada, Spain
NYU Langone Health
Celgene Corporation

Terminated

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (rev/abraxane)

Relapsed or Refractory Multiple Myeloma

United States
University of Pittsburgh
Celgene Corporation

Completed

Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit

Gram-negative Bacterial Infections

United States
Massachusetts General Hospital
Celgene Corporation

Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Acute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic Leukemia

United States
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
Celgene Corporation
Prologue Research International

Completed

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
University Hospital, Lille
Celgene Corporation

Completed

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) (IFM2010-02)

Multiple Myeloma

France
University of Rochester
Celgene Corporation

Withdrawn

Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer, Stage III

United States
University of Chicago
Celgene Corporation

Completed

Cetuximab and Lenalidomide in Head and Neck

Squamous Cell Carcinoma

United States
Southeastern Gynecologic Oncology
Celgene Corporation

Completed

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
NSABP Foundation Inc
Celgene Corporation

Completed

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

Breast Neoplasms

United States

Clinical Trials Sponsored by Centene Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations